The Next Wave of Immunotherapy in Multiple Myeloma: Bispecifics, CAR-T & Blenrep

Dr. Meera Mohan compares the three classes of immunotherapy for multiple myeloma (antibody-drug conjugates, CAR T-cell therapy, and bispecific antibodies) at the HealthTree Houston Myeloma Roundtable (October 24, 2026). She reviews belantamab mafodotin (Blenrep) and the DREAMM-7 trial, the approved BCMA and GPRC5D bispecifics, step-up dosing, cytokine release syndrome and neurotoxicity, why infection is the main long-term risk, and how IVIG antibody replacement helps. She also covers belantamab eye toxicity and the REMS program, what "cure" means to patients, and long-term remission data from CARTITUDE-1 and finite-duration bispecific therapy.